|
2022 Journal Article Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trialEvans, Thomas G, Bussey, Louise, Eagling-Vose, Elizabeth, Rutkowski, Kathryn, Ellis, Chris, Argent, Chris, Griffin, Paul, Kim, Joshua, Thackwray, Susan, Shakib, Sepehr, Doughty, Julia, Gillies, John, Wu, Jian, Druce, Julian, Pryor, Melinda and Gilbert, Sarah (2022). Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. The Lancet Infectious Diseases, 22 (6), 857-866. doi: 10.1016/S1473-3099(21)00702-7 |
|
2022 Journal Article Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epitheliumPinto, Andreia L., Rai, Ranjit K., Brown, Jonathan C., Griffin, Paul, Edgar, James R., Shah, Anand, Singanayagam, Aran, Hogg, Claire, Barclay, Wendy S., Futter, Clare E. and Burgoyne, Thomas (2022). Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. Nature Communications, 13 (1) 1609, 1-14. doi: 10.1038/s41467-022-29255-y |
|
2022 Journal Article Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adultsChughlay, M. Farouk, Barnes, Karen I., El Gaaloul, Myriam, Abla, Nada, Möhrle, Jörg J., Griffin, Paul, van Giersbergen, Paul, Reuter, Stephanie E., Schultz, Hayley B., Kress, Anita, Tapley, Peter, Webster, Rebecca A., Wells, Timothy, McCarthy, James S., Barber, Bridget E., Marquart, Louise, Boyle, Michelle J., Engwerda, Christian R. and Chalon, Stephan (2022). Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adults. Antimicrobial Agents and Chemotherapy, 66 (1) e01584-21, e0158421. doi: 10.1128/AAC.01584-21 |
|
2021 Journal Article Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccineWebster, Rebecca, Sekuloski, Silvana, Odedra, Anand, Woolley, Stephen, Jennings, Helen, Amante, Fiona, Trenholme, Katharine R., Healer, Julie, Cowman, Alan F., Eriksson, Emily M., Sathe, Priyanka, Penington, Jocelyn, Blanch, Adam J., Dixon, Matthew W. A., Tilley, Leann, Duffy, Michael F., Craig, Alister, Storm, Janet, Chan, Jo-Anne, Evans, Krystal, Papenfuss, Anthony T., Schofield, Louis, Griffin, Paul, Barber, Bridget E., Andrew, Dean, Boyle, Michelle J., de Labastida Rivera, Fabian, Engwerda, Christian and McCarthy, James S. (2021). Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 19 (1) 293, 293. doi: 10.1186/s12916-021-02150-x |
|
2021 Journal Article Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialChappell, Keith J., Mordant, Francesca L., Li, Zheyi, Wijesundara, Danushka K., Ellenberg, Paula, Lackenby, Julia A., Cheung, Stacey T. M., Modhiran, Naphak, Avumegah, Michael S., Henderson, Christina L., Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H. O., Marrero-Hernandez, Sara, Selva, Kevin J., Chung, Amy W., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D., Hogarth, P Mark, Kedzierska, Katherine ... Munro, Trent P. (2021). Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 21 (10), 1383-1394. doi: 10.1016/S1473-3099(21)00200-0 |
|
2021 Journal Article A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patientsYamada, Miko, Miller, Dennis M., Lowe, Melinda, Rowe, Casey, Wood, Dominic, Soyer, H. Peter, Byrnes-Blake, Kelly, Parrish-Novak, Julia, Ishak, Laura, Olson, James M., Brandt, Gordon, Griffin, Paul, Spelman, Lynda and Prow, Tarl W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 23 100830, 1-6. doi: 10.1016/j.conctc.2021.100830 |
|
2021 Journal Article Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South‐East QueenslandWu, Mandy, Seel, Mandy, Britton, Sumudu, Dean, Judith A., Lazarou, Mattea, Safa, Huda, Griffin, Paul and Nourse, Clare (2021). Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South‐East Queensland. Australian and New Zealand Journal of Obstetrics and Gynaecology, 62 (1) ajo.13424, 91-97. doi: 10.1111/ajo.13424 |
|
2021 Journal Article Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled studyKrishnan, Ravi, Duiker, Melanie, Rudd, Penny A., Skerrett, Donna, Pollard, James G. D., Siddel, Carolyn, Rifat, Rifat, Ng, Jennifer H. K., Georgius, Peter, Hererro, Lara J. and Griffin, Paul (2021). Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskeletal Disorders, 22 (1) 271. doi: 10.1186/s12891-021-04123-w |
|
2021 Journal Article Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparumMcCarthy, James S., Abd-Rahman, Azrin N., Collins, Katharine A., Marquart, Louise, Griffin, Paul, Kummel, Anne, Fuchs, Aline, Winnips, Cornelis, Mishra, Vishal, Csermak-Renner, Katalin, Jain, J. Prakash and Gandhi, Preetam (2021). Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 65 (2) e01423-20. doi: 10.1128/aac.01423-20 |
|
2020 Journal Article Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccineKeech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B., Haupt, Robert E., Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A., Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D., Griffin, Paul, Wilkinson, Bethanie and Glenn, Gregory M. (2020). Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. The New England Journal of Medicine, 383 (24), 2320-2332. doi: 10.1056/NEJMoa2026920 |
|
2020 Journal Article A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsAliprantis, Antonios O., Shaw, Christine A., Griffin, Paul, Farinola, Nicholas, Railkar, Radha A., Cao, Xin, Liu, Wen, Sachs, Jeffrey R., Swenson, Christine J., Lee, Heather, Cox, Kara S., Spellman, Daniel S., Winstead, Colleen J., Smolenov, Igor, Lai, Eseng, Zaks, Tal, Espeseth, Amy S. and Panther, Lori (2020). A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 17 (5), 1-14. doi: 10.1080/21645515.2020.1829899 |
|
2020 Journal Article Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO studyHenderson, A., Paterson, D. L., Chatfield, M. D., Tambyah, P. A., Lye, D. C., De, P. P., Lin, R. T. P., Chew, K. L., Yin, M., Lee, T. H., Yilmaz, M., Cakmak, R., Alenazi, T. H., Arabi, Y. M., Falcone, M., Bassetti, M., Righi, E., Rogers, B.A., Kanj, S. S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T. H., Looke, D. F. M., Runnegar, N. J., Miyakis, S., Walls, G., AI Khamis, M., Zikri, A. ... For the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2020). Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. Clinical Infectious Diseases, 73 (11), e3842-e3850. doi: 10.1093/cid/ciaa1479 |
|
2020 Journal Article Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trialLickliter, Jason, Kanceva, Radmila, Vincent, Emmanuelle, Schueler, Armin, Harrison-Moench, Eleanor, Yue, Corinne Seng, Stahl, Michael, Ullmann, Martin, Ghori, Vishal and Griffin, Paul (2020). Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trial. Clinical Therapeutics, 42 (8), 1508-1518.e1. doi: 10.1016/j.clinthera.2020.05.020 |
|
2020 Journal Article Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infectionCollins, Katharine A., Abd-Rahman, Azrin N., Marquart, Louise, Ballard, Emma, Gobeau, Nathalie, Griffin, Paul, Chalon, Stephan, Möhrle, Jörg J. and McCarthy, James S. (2020). Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infection. The Journal of Infectious Diseases, 225 (6), 1062-1069. doi: 10.1093/infdis/jiaa287 |
|
2020 Journal Article Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 studyPlayford, Elliott Geoffrey, Munro, Trent, Mahler, Stephen M., Elliott, Suzanne, Gerometta, Michael, Hoger, Kym L., Jones, Martina L., Griffin, Paul, Lynch, Kathleen D., Carroll, Heidi, El Saadi, Debra, Gilmour, Margaret E., Hughes, Benjamin, Hughes, Karen, Huang, Edwin, de Bakker, Christopher, Klein, Reuben, Scher, Mark G., Smith, Ina L., Wang, Lin-Fa, Lambert, Stephen B., Dimitrov, Dimiter S., Gray, Peter P. and Broder, Christopher C. (2020). Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. The Lancet Infectious Diseases, 20 (4), 445-454. doi: 10.1016/S1473-3099(19)30634-6 |
|
2020 Journal Article A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteersMcCarthy, James S., Rückle, Thomas, Elliott, Suzanne L., Ballard, Emma, Collins, Katharine A., Marquart, Louise, Griffin, Paul, Chalon, Stephan and Möhrle, Jörg J. (2020). A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers. Antimicrobial Agents and Chemotherapy, 64 (1) e01371-19, e01371-19. doi: 10.1128/AAC.01371-19 |
|
2019 Journal Article Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I/IIa trialChandra, Janin, Woo, Wai-Ping, Dutton, Julie L., Xu, Yan, Li, Bo, Kinrade, Sally, Druce, Julian, Finlayson, Neil, Griffin, Paul, Laing, Kerry J., Koelle, David M. and Frazer, Ian H. (2019). Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I/IIa trial. PLoS One, 14 (12) e0226320, 1-20. doi: 10.1371/journal.pone.0226320 |
|
2019 Journal Article DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparumCollins, Katharine A., Rueckle, Thomas, Elliott, Suzanne, Marquart, Louise, Ballard, Emma, Chalon, Stephan, Griffin, Paul, Moehrle, Joern J. and McCarthy, James S. (2019). DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 63 (4) e01837-18. doi: 10.1128/AAC.01837-18 |
|
2019 Journal Article Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trialsManton, Kerry J., Gauld, Cassandra S., White, Katherine M., Griffin, Paul M. and Elliott, Suzanne L. (2019). Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open, 9 (1) e024224, e024224. doi: 10.1136/bmjopen-2018-024224 |
|
2018 Journal Article Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trialHarris, Patrick N. A., Tambyah, Paul A., Lye, David C., Mo, Yin, Lee, Tau H., Yilmaz, Mesut, Alenazi, Thamer H., Arabi, Yaseen, Falcone, Marco, Bassetti, Matteo, Righi, Elda, Rogers, Benjamin A., Kanj, Souha, Bhally, Hasan, Iredell, Jon, Mendelson, Marc, Boyles, Tom H., Looke, David, Miyakis, Spiros, Walls, Genevieve, Al Khamis, Mohammed, Zikri, Ahmed, Crowe, Amy, Ingram, Paul, Daneman, Nick, Griffin, Paul, Athan, Eugene, Lorenc, Penelope, Baker, Peter ... MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2018). Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA, 320 (10), 984-994. doi: 10.1001/jama.2018.12163 |
